BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/17/2021 8:56:01 AM | Browse: 338 | Download: 707
 |
Received |
|
2021-09-08 11:31 |
|
Peer-Review Started |
|
2021-09-08 11:32 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-10-16 03:46 |
|
Revised |
|
2021-10-28 17:10 |
|
Second Decision |
|
2021-11-30 03:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-11-30 19:01 |
|
Articles in Press |
|
2021-11-30 19:01 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-11-26 19:39 |
|
Typeset the Manuscript |
|
2021-12-15 01:40 |
|
Publish the Manuscript Online |
|
2021-12-17 08:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jun-Xi Xu, De-Hao Wu, Li-Wei Ying and Han-Guang Hu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Han-Guang Hu, PhD, Academic Fellow, Associate Chief Physician, Doctor, Professor, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. huhanguang@zju.edu.cn |
| Key Words |
Gastrointestinal tract; Pancreas; Immune checkpoint inhibitors; Immunotherapy; Neuroendocrine tumors; Cytotoxic T-lymphocyte-associated protein 4 antigen |
| Core Tip |
Several evaluations have been published on immunotherapy for neuroendocrine neoplasms. However, this is the first review to specifically focus on the efficacy of different immunotherapy strategies such as immune checkpoint inhibitor (ICI) monotherapy, dual ICI therapy, anti-angiogenesis plus ICI, and chemotherapy combined with ICI for the treatment of advanced well-differentiated high-grade gastroenteropancreatic neuroendocrine tumors. |
| Publish Date |
2021-12-17 08:56 |
| Citation |
Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 |
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i47/8123.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i47.8123 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
